Year: 2021

WisdomTree Launches Diversified Crypto Exposures in the U.S. and Europe

Written by Customer Service on December 3, 2021. Posted in Public Companies.

WisdomTree’s innovative crypto indices underpin three new European crypto ETPs plus separate account exposures to U.S. investors through a collaboration with Ritholtz Wealth Management, powered by OnRamp NEW YORK, Dec. 03, 2021 (GLOBE NEWSWIRE) — WisdomTree Investments, Inc. (NASDAQ: WETF), an exchange-traded fund (“ETF”) and exchange-traded product (“ETP”) sponsor and asset manager, announced an extension of its digital asset thought leadership through the creation of four new crypto indices that will underpin offerings for diversified crypto exposures for investors in both the U.S. and European markets. U.S. – WisdomTree Crypto IndexRWM WisdomTree Crypto IndexEurope – WisdomTree ETPs Tracking a WisdomTree Crypto IndexWisdomTree Crypto Mega Cap Equal Weight (MEGA) WisdomTree Crypto Market (BLOC) WisdomTree Crypto...

Appian Announces Planned Retirement of CFO, Mark Lynch, and Reaffirms Guidance for Q4 and Full Year 2021

Written by Customer Service on December 3, 2021. Posted in Public Companies.

MCLEAN, Va., Dec. 03, 2021 (GLOBE NEWSWIRE) — Appian (NASDAQ: APPN), today announced that Mark Lynch intends to retire from his role as Chief Financial Officer effective March 31, 2022. Mr. Lynch will remain in his current position through March 31, 2022, to assist with the filing and certification of the Company’s annual report on Form 10-K, and to support with the transition of his responsibilities to his successor, once named. “Mark has been Appian’s CFO for half the lifetime of the Company. He’s a tremendous executive and a good friend. He’s earned the trust and confidence of our employees and our investors. We appreciate his wisdom, professionalism, and sense of humor — and we wish him well in his retirement,” said Matt Calkins, Appian’s Chairman and CEO. Mr. Lynch joined Appian as CFO in 2009 and has...

GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress

Written by Customer Service on December 3, 2021. Posted in Public Companies.

Nonhuman Primate Testing of Sudan and Marburg Vaccine Candidates Demonstrates Efficacious Immune Response ATLANTA, GA, Dec. 03, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, presented data from ongoing studies of its investigational vaccines against hemorrhagic fevers (Sudan, Ebola, & Marburg) at the recent World Vaccine & Immunotherapy Congress, held November 30 – December 2 in San Diego, California. The presentation, titled “Design and Evaluation of Vaccines Against Hemorrhagic Fevers using the MVA-VLP Platform”, was delivered by Mary Hauser, PhD, GeoVax Senior Scientist. In her talk, Dr. Hauser discussed the preclinical efficacy of GeoVax’s vaccines against Sudan (SUDV) and Marburg (MARV)...

RENNOVA HEALTH, INC. OWNED HOSPITAL RECEIVES CRITICAL ACCESS HOSPITAL CERTIFICATION

Written by Customer Service on December 3, 2021. Posted in Public Companies.

WEST PALM BEACH, Fla., Dec. 03, 2021 (GLOBE NEWSWIRE) — Rennova Health, Inc. (OTC: RNVA) today announced that the application by its hospital, Scott County Community Hospital, Inc. (DBA Big South Fork) in Oneida, TN, for designation as a Critical Access Hospital (CAH) has been approved by Centers for Medicare and Medicaid Services (CMS). The effective date of approval is retrospective to June 30, 2021. CAH status means the hospital will be entitled to a cost-based reimbursement from Medicare, which has the potential to increase revenue. There are a number of benefits of CAH including that capital improvement costs are included in allowable costs for determining Medicare reimbursement. This special reimbursement that CAHs receive is intended to improve their financial performance and thereby maintain access to basic health care...

Northrim BanCorp, Inc. Declares Quarterly Cash Dividend of $0.38 per Share

Written by Customer Service on December 3, 2021. Posted in Dividend Reports And Estimates.

ANCHORAGE, Alaska, Dec. 03, 2021 (GLOBE NEWSWIRE) — Northrim BanCorp, Inc. (NASDAQ: NRIM) today announced that the Board of Directors declared a regular quarterly cash dividend of $0.38 per share. The dividend will be payable on December 23, 2021, to shareholders of record at the close of business on December 16, 2021. “We are committed to providing returns to our shareholders through consistent quarterly cash dividends,” said Joe Schierhorn, President and CEO. At the stock price of $44.30 per share at the close of the market on December 2, 2021, the current dividend equates to a yield of 3.43% on an annualized basis. October 29, 2021, Northrim reported net income of $8.88 million, or $1.42 per diluted share, in the third quarter of 2021, compared to $8.35 million, or $1.33 per diluted share, in the second quarter of 2021, and...

Victory Square Technologies To Issue Second Tranche of Special Common Share Dividend of its Interest in Portfolio Company Fantasy 360 Technologies Inc. in December 2021

Written by Customer Service on December 3, 2021. Posted in Dividend Reports And Estimates.

Not for distribution to United States newswire services or for dissemination in the United States VANCOUVER, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square” or “VST” or “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) is pleased to announce that, further to its news release dated August 12, 2021, the company will issue the second tranche of its previously announced special dividend of common shares in the capital of its portfolio company Fantasy 360 Technologies Inc. (“Immersive”) to shareholders of Victory Square in December 2021. The second tranche will consist of approximately an additional 4,500,000 Immersive Shares which will be eligible to Victory Square shareholders of record as of a date to be determined by Victory Square. Victory Square already Issued a special common share...

SCYNEXIS Reports the Exercise of Warrants Totalling $7.9 Million

Written by Customer Service on December 3, 2021. Posted in Public Companies.

JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported the exercise of warrants to purchase 1.2 million shares of SCYNEXIS common stock by Federated Hermes Kaufmann Small Cap Fund and Dafna Lifescience LP for which SCYNEXIS accepted a reduced exercise price. Proceeds to SCYNEXIS are approximately $7.9 million. The exercised warrants were issued in SCYNEXIS’s December 2019 financing. The remaining warrants issued in the December 2019 financing covering approximately 3.2 million shares of common stock expired unexercised on December 2, 2021. “We believe the exercise of warrants by two of our largest stockholders provides a significant sign of confidence in the...

AiXin Life International, Inc. (OTCQX: AIXN) Launches Antibacterial Product to Facilitate Prevention and Control of Covid-19

Written by Customer Service on December 3, 2021. Posted in Public Companies.

CHENGDU, CHINA, Dec. 03, 2021 (GLOBE NEWSWIRE) — AiXin Life International, Inc. (OTCQX: AIXN) (hereinafter referred to as “AIXN” or the “Company”), a Company that specializes in providing nutritional products to the Chinese market as well as advertising and marketing services to distributors, today announced that it jointly hosted the launch of a new anti-bacterial agent, with this product being unveiled at the Chengdu AiXin Shangyan Hotel in November 2021.AIXN Chairman & CEO Mr. Quanzhong LinIn the current pandemic situation, companies and governments work together to contribute to the prevention and elimination of Covid-19, and help economies resume work and production. AIXN, in collaboration with various government scientific research institutions and enterprises, jointly hosted the “Zhongyixin Antimicrobial...

Form 8 (OPD) Invesco Ltd. Form 8.3 Clinigen Group Plc

Written by Customer Service on December 3, 2021. Posted in Mergers And Acquisitions.

Opening Position Disclosure FORM 8.3 PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION (a) Full name of discloser: Invesco Ltd. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Clinigen Group Plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:For an opening position disclosure, state the...

Patriot Glass Solutions, a Division of C-Bond Systems, Receives Purchase Order Through One of its Premier Distributors for C-Bond Ballistic-Resistant System for Fortune 500 Customer in San Francisco Bay Area

Written by Customer Service on December 3, 2021. Posted in Public Companies.

Orders Like This Highlight the Increasing Need for Security Solutions like C-Bond BRS to Help Prevent Break-ins, Smash-and-Grab Robberies, Looting, and Gunfire HOUSTON, Dec. 03, 2021 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, announced today that its Patriot Glass Solutions division received a purchase order through one of its premier distributors for C-Bond BRS (ballistic-resistant system) for a Fortune 500 customer in the San Francisco Bay Area. The customer is installing C-Bond BRS at its corporate headquarters. Patriot Glass Solutions’ leading products are C-Bond BRS, a ballistic-resistant film system, and C-Bond Secure, a multi-purpose glass strengthening primer and window film mounting solution that deters forced entry. “This Fortune 500 customer is taking...

Year: 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals